

HCC: Advances in diagnosis and prognosis

HCC The New Pathological Approach

Valérie Paradis Pathology Dpt, Hôpital Beaujon Inserm U1149 / CRI, DHU UNITY, FHU MOSAIC, Paris











From Conventional Histology to Molecular Pathology




Pathomolecular Classification of Hepatocellular Adenomas



From 2006 to 2020

Molecular Pathology in HCC


Intertumor heterogeneity & Spatial Intratumor heterogeneity



- > A key-issue in cancer medicine
 - Impacts accurate diagnosis, prognosis and response to therapy
 - Mostly explored at the genetic level by highthroughput NGS technologies
 - Using bulk tumor specimens
 - Ignoring cell heterogeneity and spatial organization
 - The need to develop and use in situ approaches (Molecular Pathology)

Pathomolecular Classification of HCC

2.



Diagnosis of early HCC (< 2 cm)

Access to curative treatments

Exhaustive characterisation of HCC

Improve patient management

1. DIAGNOSIS OF EARLY HCC (< 2 CM)

Hepatocellular nodules < 2 cm arising in cirrhosis A wide spectrum of nodules (from regenerative to HCC)

Histological features

Cytologic features Small cell change Large cell change Clonelike foci (clear, fatty)

Architectural features

Plate thickening ≥3 cells Increased cell density compared with surroundings Pseudoglands Nodule-in-nodule Portal tract Unpaired arteries and capillarized sinusoids^a Stromal invasion^b Reticulin framework Immunophenotypical features




All 3 markers +ve (100% specificity, 72% sensitivity)

Accurate diagnosis of nodules < 2 cm remains challenging in some cases (biopsy specimen)

Park NY Arch Pathol Lab Med 2011, Di Tommaso L J Hepatol 2009, Tremosini S Gut 2012, Di Tommaso L Hepatology 2011


Need for Additional Tissue Biomarkers



- Main mechanism of telomerase reactivation
- A prerequisite for malignant transformation
- The most frequent mutations in liver carcinogenesis
 - Increasing rate from cirrhosis (0%), LGDN (6%), HGDN (19%) to eHCC (61%)

Nault JC Hepatology 2014; Zucman-Rossi J Gastroenterology 2015

Surrogate tissue biomarkers of TERT promoter mutations in nodules < 2 cm using MALDI imaging (global in situ proteomic approach)



 11 protein peaks correlated with TERT promoter mutations
 S Paisley (manuscript in prep.)

2. EXHAUSTIVE CHARACTERISATION OF HCC


HCC : A Wide Spectrum of Tumors



WHO classification of tumours of the liver and intrahepatic bile ducts


Malignant hepatocellular tumours and precursors

- 8170/3 Hepatocellular carcinoma NOS
 8171/3 Hepatocellular carcinoma, fibrolamellar
 8172/3 Hepatocellular carcinoma, scirrhous
 8174/3 Hepatocellular carcinoma, clear cell type
 Hepatocellular carcinoma, steatohepatitic
 Hepatocellular carcinoma, macrotrabecular
 massive
 Hepatocellular carcinoma, chromophobe
 Hepatocellular carcinoma, chromophobe
 - Hepatocellular carcinoma, neutrophil-rich Hepatocellular carcinoma, lymphocyte-rich
- 8970/3 Hepatoblastoma NOS



WHO (5th edition, 2019)

From Calderaro J J Hep 2020



Calderaro J J Hepatol 2017

Macrotrabecular-Massive HCC (MTM-HCC, G3)


TP53 mutations



- PI3K/AKT pathway activation
- Increased cell proliferation
- EMT activation
- Angiogenesis activation


Prognostic impact 284 HCC (Biopsy pre-RFA)

 \succ




Ziol M Hepatology 2017

ESM-1 A good surrogate marker of MTM-HCC



Sst 93%, Spe 91%, Kappa 0.77

Calderaro J Clin Cancer Res 2019



Calderaro J J Hepatol 2017

Well-differentiated Cholestatic HCC (G5-G6)


CTNNB1 mutations (exon 3)




Molecular features

- B-catenin pathway activation
- IL6/ JAK/STAT pathway downregulation
- Maintenance of hepatocellular differentiation & function
- Low proliferation
- Dysregulated expression of bile salt transporters

Clinical implication (HCC patients with immune checkpoint inhibitors)




Harding J J Clin Cancer Res 2018



Calderaro J J Hepatol 2017


Steatohepatitic HCC (G4)



- Molecular features
- No specific genetic abnormalities
- Lack of Wnt/β-catenin pathway activation
- Activation of IL6/JAK/STAT pathway


Less agressive phenotype (microvascular invasion, satellite nodules)

Beaujon experience 298 HCC (39 SH-HCC)



Surrogate Markers of Prognosis In progress (need validation)


Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study



- At least 2 +ve markers: sst 72 %, spe 64%
- 3 +ve markers: sst 36%, Spe 90%

Poté N et al Hepatology 2013, J Hepatol 2015 & Liver Int 2017

Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma CD34 (>55% of tumor area)



 Correlated with AFP, tumor size, MTM-HCC, microvascular invasion

Renne SL Hepatology 2020

Performance of Tumor Biopsy

> Sampling variability : a major issue


- Biopsy may miss Intratumor heterogeneity
 - Present in 2/3 of HCC (morphological & molecular levels) *
 - More frequent in larger tumors
- Adapt the procedure according to the HCC macroscopic features (imaging) ?

Expertise of pathologist

- Usefulness of panel of immunomarkers
 - Diagnosis and prognosis
- Analysis of non tumoral liver

* Friemel J et al Clin Cancer Res 2014

Gene expression signature (Nanostring[®], 200 genes) Correlation between 12-paired surgical and biopsy specimens [0.97 (0.87-0.95)]



Beaufrère A, submitted (collab. J Zucman-Rossi lab)


Conclusions Pathomolecular Classification of HCC

> From Classical histology to Molecular pathology

- Provides an exhaustive characterisation of HCC, including prognostic features
 - Already applied for subtyping Hepatocellular adenomas
- Several tissue biomarkers available, some of them needed to be independently validated
- Relevant approach for considering intratumoral heterogeneity
- Towards IMAGOMICS



Multiscale Optimized Strategy for Artificial Intelligence-based Imaging Biomarkers in Digestive Cancer







Inserm U 1149 / CRI

From inflammation to cancer in digestive diseases »

V Paradis

- A Couvelard, N Guedj, J Cros, V Rebours, A Beaufrère
- A Hammoutène (Post-doc)
- F Cauchy, S Frendi, E Gigante, L de Mestier (Doc)
- M Tabard (M2)
- S Laouirem, C de Flori, H Cazier, M Albuquerque (IE)

Beaujon hospital

Pathology (V Paradis)

Radiology (V Vilgrain) Hepatology (F Durand)

- Surgery (O Soubrane)
- Oncology (M Bouattour)









